- Home
- ALV vs ROIV Comparison
ALV vs ROIV Comparison
Compare ALV & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALV
- ROIV
- Stock Information
- Founded
- ALV 1953
- ROIV 2014
- Country
- ALV Sweden
- ROIV United Kingdom
- Employees
- ALV N/A
- ROIV N/A
- Industry
- ALV Auto Parts:O.E.M.
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- ALV Consumer Discretionary
- ROIV Health Care
- Exchange
- ALV Nasdaq
- ROIV Nasdaq
- Market Cap
- ALV 9.7B
- ROIV 8.6B
- IPO Year
- ALV 1997
- ROIV N/A
- Fundamental
- Price
- ALV $126.68
- ROIV $15.09
- Analyst Decision
- ALV Buy
- ROIV Strong Buy
- Analyst Count
- ALV 9
- ROIV 9
- Target Price
- ALV $125.22
- ROIV $19.94
- AVG Volume (30 Days)
- ALV 520.1K
- ROIV 8.2M
- Earning Date
- ALV 10-17-2025
- ROIV 11-11-2025
- Dividend Yield
- ALV 2.72%
- ROIV N/A
- EPS Growth
- ALV 21.77
- ROIV N/A
- EPS
- ALV 9.16
- ROIV N/A
- Revenue
- ALV $10,462,000,000.00
- ROIV $23,233,000.00
- Revenue This Year
- ALV $3.64
- ROIV N/A
- Revenue Next Year
- ALV $4.06
- ROIV $248.22
- P/E Ratio
- ALV $13.64
- ROIV N/A
- Revenue Growth
- ALV N/A
- ROIV N/A
- 52 Week Low
- ALV $75.49
- ROIV $8.73
- 52 Week High
- ALV $127.89
- ROIV $16.05
- Technical
- Relative Strength Index (RSI)
- ALV 62.42
- ROIV 78.02
- Support Level
- ALV $124.26
- ROIV $13.81
- Resistance Level
- ALV $127.32
- ROIV $16.05
- Average True Range (ATR)
- ALV 2.07
- ROIV 0.50
- MACD
- ALV -0.32
- ROIV 0.22
- Stochastic Oscillator
- ALV 79.34
- ROIV 77.14
About ALV Autoliv Inc.
Autoliv Inc is the world-wide leader in passive safety components and systems for the auto industry. Products include seat belts, frontal air bags, side-impact air bags, air bag inflators, and steering wheels. The Renault-Nissan-Mitsubishi alliance is the company's largest customer at 10% of 2023 revenue, with Stellantis accounting for 10% and Volkswagen 9%. At 34% of 2023 revenue, the Americas was Autoliv's largest geographic region, followed by Europe at 27%, China at 20%, and rest of world at 19%.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.